The biomarker discovery pipeline is broken. How can we change it?
During his keynote at the Breath Biopsy Conference 2021, Patrick Bossuyt asserted that the biomarker discovery pipeline is broken meaning – that a lot of research effort is being spent on early-stage biomarker research with few successful outputs into clinical practice. His presentation includes a number of reasons for this inefficiency, including the use of spin by researchers to emphasize the potential and promise of their work.
Do you agree that the biomarker pipeline is broken? Why is this, and how could biomarker research be changed to improve success?